1
|
Yang Y, Zhao L, Wang T, Zheng X, Wu Y. Biological activity and structural modification of isosteviol over the past 15 years. Bioorg Chem 2024; 143:107074. [PMID: 38176378 DOI: 10.1016/j.bioorg.2023.107074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Revised: 12/03/2023] [Accepted: 12/27/2023] [Indexed: 01/06/2024]
Abstract
Isosteviol is a tetracyclic diterpenoid obtained by hydrolysis of stevioside. Due to its unique molecular skeleton and extensive pharmacological activities, isosteviol has attracted more and more attention from researchers. This review summarized the structural modification, pharmacological activity and microbial transformation of isosteviol from 04/2008 to 10/2023. In addition, the research history, structural characterization, and pharmacokinetics of isosteviol were also briefly reviewed. This review aims to provide useful literature resources and inspirations for the exploration of diterpenoid drugs.
Collapse
Affiliation(s)
- Youfu Yang
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, PR China
| | - Lijun Zhao
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, PR China
| | - Tongsheng Wang
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, PR China
| | - Xiaoke Zheng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, PR China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Zhengzhou 450046, PR China.
| | - Ya Wu
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, PR China; The Engineering and Technology Center for Chinese Medicine Development of Henan Province, Zhengzhou 450046, PR China.
| |
Collapse
|
2
|
Adehin A, Tan KS, Zou C, Lu Z, Lin Y, Wang D, Cheng Q, Tan W. A compartmental approach to isosteviol's disposition in Sprague-Dawley rats. Naunyn Schmiedebergs Arch Pharmacol 2019; 393:1003-1011. [PMID: 31820053 DOI: 10.1007/s00210-019-01757-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Accepted: 10/30/2019] [Indexed: 10/25/2022]
Abstract
Isosteviol has been reported to reverse hypertrophy and related inflammatory responses in in vitro models representative of cardiac muscle cells. The disposition of isosteviol is, however, characterized by secondary peaks and long plasma residence time despite reports of a relatively short half-life in liver fractions. The present study describes a compartmental approach to modelling the secondary peaks characteristic of isosteviol's concentration-time data in Sprague-Dawley rats. Oral (4 mg/kg) and intravenous (4 mg/kg) doses of isosteviol were administered to male and female Sprague-Dawley rats. Plasma samples collected between 0 and 72 h, and total bile secreted in 24 h, were analysed for isosteviol content with LC-MS/MS techniques. The disposition of isosteviol was, thereafter, described with a structural model that accounted for the sampling, liver and biliary secretion compartments, with a gap-time characterizing the accumulation and subsequent emptying of isosteviol for re-absorption. The half-life of isosteviol following oral dosing was about 103% greater in female rats than in the male, and the model-derived area under the concentration-time curve (AUC) in 72 h was about 756% greater in female animals than in males. Following the administration of intravenous doses of isosteviol, half-life and AUC in 24 h were about 332% and 595%, respectively, higher in female rats than in males. Isosteviol equivalent secreted into bile over 24 h accounted for about 94% of orally administered dose in male rats, and about 59% of oral dose in females. These findings show a differential systemic removal of isosteviol in Sprague-Dawley rats, likely explainable by gender-related differences in the glucuronidation-capacity of isosteviol.
Collapse
Affiliation(s)
- Ayorinde Adehin
- Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.,Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria
| | - Keai Sinn Tan
- Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China
| | - Chengjuan Zou
- Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China
| | - Zhiqiang Lu
- Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China
| | - Yue Lin
- Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China
| | - Dongfang Wang
- Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China
| | - Qing Cheng
- Dermatology Hospital, Southern Medical University, Guangzhou, China
| | - Wen Tan
- Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
| |
Collapse
|
3
|
In vitro metabolic stability and biotransformation of isosteviol in human and rat liver fractions. Drug Metab Pharmacokinet 2019; 34:194-200. [PMID: 30880146 DOI: 10.1016/j.dmpk.2019.02.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Revised: 02/17/2019] [Accepted: 02/25/2019] [Indexed: 12/18/2022]
Abstract
Isosteviol is a lead compound whose cardioprotective property has been partly explained by its regulation of ion channels and interference with signalling pathways in the metabolism of some fatty acids. This study determined the metabolic stability of isosteviol in human liver microsomes and H9c2 cell line, and the identity of its metabolites in human and rat liver fractions. Isosteviol was largely unmetabolized in H9c2 cells and in NADPH-only supplemented human liver fractions, suggesting a very limited contribution of phase I biotransformation to its hepatic clearance. The in vitro half-life of isosteviol in UDPGA-only supplemented medium was observed to be 24.9 min with an estimated intrinsic clearance of 0.349 mL/min/kg in man. Analysis by LC-MS/MS and Q-tof showed that isosteviol is mainly metabolised to its acyl-β-D-glucuronide in humans and rats. Mono-hydroxy-isosteviol and dihydroisosteviol were also identified. Rat liver fraction, however, generated dihydroxy-isosteviol in addition to two mono-hydroxy derivatives. Further studies confirmed that dihydroisosteviol is subsequently biotransformed to its acyl-β-D-glucuronide in man and rat. These findings suggest that future studies of the efficacy and toxicity of isosteviol might have to consider xenobiotics that alter the glucuronidation pathways significantly in man.
Collapse
|
4
|
Kachingwe BH, Wang LH, Uang YS, Huang TJ, Lin SJ. Dose-dependent pharmacokinetics and tentative identification of urine metabolites from an isosteviol derivative with anti-hepatitis B activity in rats. Biomed Chromatogr 2018; 32:e4266. [PMID: 29689637 DOI: 10.1002/bmc.4266] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Revised: 04/11/2018] [Accepted: 04/14/2018] [Indexed: 11/06/2022]
Abstract
Compound 1 (ent-16-oxobeyeran-19-N-methylureido) is a semisynthetic isosteviol derivative that shows anti-hepatitis B virus activity in Huh7 cells by affecting viral DNA transcription and the Toll-like receptor 2/nuclear factor-κB signaling pathway. Thus, the pharmacokinetics and metabolite identification were studied as part of the discovery and development process of compound 1. The pharmacokinetics was evaluated after administration to rats at an intravenous dose of 2 mg/kg, and oral doses of 2, 5 and 10 mg/kg. Plasma concentrations were determined using LC-MS/MS. Moreover, urine samples from rats dosed at 10 mg/kg were scanned for metabolites using UPLC-QTOF-MS/MS. Results for the intravenously administered dose of 2 mg/kg showed that the area under the concentration-time curve was 65,223.31 ± 4269.80 ng min/mL, and the systemic clearance was 0.031 ± 0.0021 L/min. Oral pharmacokinetic parameters were dose-dependent, showing nonproportional increases in the oral AUCs with respective values of 4371.62 ± 3084.81, 22,472.75 ± 9103.33 and 135,141.83 ± 38,934.03 ng min/mL for 2, 5 and 10 mg/kg. The bioavailability was low at 1.5% for 2 mg/kg dose, and at 1.1% for both 5 and 10 mg/kg doses. Metabolites excreted in the urine indicate possible N-oxidation and glucuronide conjugation.
Collapse
Affiliation(s)
- Baxter Hepburn Kachingwe
- School of Pharmacy, Taipei Medical University, Taipei, Taiwan
- Department of Pharmacy, College of Medicine, University of Malawi, Blantyre, Malawi
| | - Li-Hsuan Wang
- School of Pharmacy, Taipei Medical University, Taipei, Taiwan
| | - Yow-Shieng Uang
- Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
- Rosetta Pharmamate Co. Ltd, Taipei, Taiwan
| | | | - Shwu-Jiuan Lin
- School of Pharmacy, Taipei Medical University, Taipei, Taiwan
- PhD Program in Clinical Drug Development of Chinese Herbs Medicine, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
| |
Collapse
|
5
|
Lai W, Kang Q, Zou C, Li Q, Sun H, Tan W. Development of a liquid formulation of poorly water-soluble isosteviol sodium using the co-solvent technology. Pharm Dev Technol 2016; 22:275-282. [PMID: 27557399 DOI: 10.1080/10837450.2016.1226900] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
An intravenously injectable liquid formulation of the poorly water-soluble isosteviol sodium (ISVNa) that has a great clinical potential for cardiovascular diseases was developed using the co-solvent technology. The pH and composition of the co-solvent were optimized to obtain a stable liquid formulation (termed as STVNa) based on saline at pH 10.0 containing 25% (v/v) of ethanol and 20% (v/v) of propylene glycol. STVNa was physicochemically stable upon storage for more than 3 months under various conditions. In vitro studies showed that STVNa did not induce hemolytic effects up to 9.1% (v/v) after 3 h of incubation and it was cytocompatible up to 50 μg/mL in H2C9 cells. Furthermore, STVNa showed acceptable safety and pharmacokinetic parameters comparable with those of ISVNa in saline (dissolved at 60 °C) upon i.v. injection in Wistar rats. Overall, the results demonstrated that STVNa is a promising formulation of ISVNa for clinical translation.
Collapse
Affiliation(s)
- Wenshi Lai
- a School of Bioscience and Bioengineering, South China University of Technology , Guangzhou , China.,b Pre-incubator for Innovative Drugs and Medicine, South China University of Technology , Guangzhou , China
| | - Qiuhong Kang
- a School of Bioscience and Bioengineering, South China University of Technology , Guangzhou , China.,b Pre-incubator for Innovative Drugs and Medicine, South China University of Technology , Guangzhou , China
| | - Chengjuan Zou
- a School of Bioscience and Bioengineering, South China University of Technology , Guangzhou , China.,b Pre-incubator for Innovative Drugs and Medicine, South China University of Technology , Guangzhou , China
| | - Qingrui Li
- a School of Bioscience and Bioengineering, South China University of Technology , Guangzhou , China.,b Pre-incubator for Innovative Drugs and Medicine, South China University of Technology , Guangzhou , China
| | - Huiting Sun
- a School of Bioscience and Bioengineering, South China University of Technology , Guangzhou , China.,b Pre-incubator for Innovative Drugs and Medicine, South China University of Technology , Guangzhou , China
| | - Wen Tan
- a School of Bioscience and Bioengineering, South China University of Technology , Guangzhou , China.,c Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology , Guangzhou , China
| |
Collapse
|
6
|
Rowe A, Zhang L, Hussain A, Braet F, Ramzan I. Assessment and histological analysis of the IPRL technique for sequential in situ liver biopsy. COMPARATIVE HEPATOLOGY 2011; 10:7. [PMID: 21819626 PMCID: PMC3199742 DOI: 10.1186/1476-5926-10-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/10/2010] [Accepted: 08/08/2011] [Indexed: 11/10/2022]
Abstract
BACKGROUND The isolated perfused rat liver (IPRL) is a technique used in a wide range of liver studies. Typically livers are assessed at treatment end point. Techniques have been described to biopsy liver in the live rat and post-hepatectomy. RESULTS This paper describes a technique for obtaining two full and one partial lobe biopsies from the liver in situ during an IPRL experiment. Our approach of retaining the liver in situ assists in minimising liver capsule damage, and consequent leakage of perfusate, maintains the normal anatomical position of the liver during perfusion and helps to keep the liver warm and moist. Histological results from sequential lobe biopsies in control perfusions show that cytoplasmic vacuolation of hepatocytes is a sign of liver deterioration, and when it occurs it commences as a diffuse pattern which tends to develop a circumscribed, centrilobular pattern as perfusion progresses. CONCLUSIONS Liver lobe biopsies obtained using this method can be used to study temporal effects of drug treatments and are suitable for light and electron microscopy, and biochemical analyses.
Collapse
Affiliation(s)
- Anthony Rowe
- Faculty of Pharmacy, University of Sydney, NSW 2006, Australia.
| | | | | | | | | |
Collapse
|